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Aims While angiotensin II-infused mice are the most popular model for preclinical aneurysm research, representative data on
incidence, severity, and mortality of dissecting abdominal aortic aneurysms (AAAs) have never been established, and
the influence of confounding factors is unknown.
Methods and
Results
We performed a meta-analysis including 194 manuscripts representing 1679 saline-infused, 4729 non-treated angioten-
sin II-infused, and 4057 treated angiotensin II-infused mice. Incidence (60%) and mortality (20%) rates are reported
overall as well as for grade I (22%), grade II (26%), grade III (29%), and grade IV (24%) aneurysms. Dissecting AAA in-
cidence was significantly (P, 0.05) influenced by sex, age, genetic background, infusion time, and dose of angiotensin II.
Mortality was influenced by sex, genetic background, and dose, but not by age or infusion time. Surprisingly, both in-
cidence and mortality were significantly different (P, 0.05) when comparing angiotensin II-infused mice in descriptive
studies (56% incidence and 19% mortality) with angiotensin II-infused mice that served as control animals in treatment
studies designed to either enhance (35% incidence and 13% mortality) or reduce (73% incidence and 25% mortality)
dissecting AAA formation. After stratification to account for confounding factors (selection bias), the observed effect
was still present for incidence, but not for mortality. Possible underlying causes are detection bias (non-uniform def-
inition for detection and quantification of dissecting AAA in mice) or publication bias (studies with negative results, re-
lated to incidence in the control group, not being published).
Conclusions Our data provide a new meta-analysis-based reference for incidence and mortality of dissecting AAA in angiotensin II-
infused mice, and indicate that treatment studies using this mouse model should be interpreted with caution.
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1. Introduction
In clinical practice, abdominal aortic aneurysm (AAA) is defined as a fo-
cal dilatation of the aortic diameter larger than 1.5 times the original
size.1 Owing to the asymptomatic nature of the disease, human data
are scarce, especially at an early stage. Therefore, animal models of an-
eurysm formation are often used for preclinical research.2 The angio-
tensin II-infused mouse model is the most popular mouse model for
aneurysm research, because it reproduces many important features
such as macrophage infiltration, medial elastolysis, luminal expansion,
and thrombus formation.3 –5
Since the first paper published by Daugherty et al.3 in 2000, this
mouse model has been the subject of numerous papers, ranging
from the genetic6 – 10 over the molecular2,11 – 25 to the macroscopic
level.26– 34 Lesion severity has been reported to vary substantially with-
in this mouse model, leading to a subdivision into grade I– IV aneurysms
based on morphological characteristics that were visually observed on
excised tissue samples.20 Over time, a wide range of incidence, severity,
and mortality rates has been reported for this mouse model, but refer-
ence data are lacking. Moreover, while several confounding factors
(sex, age, and diet) seem to be the same as in human disease, their effect
on murine aneurysm pathology has never been quantified.
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The angiotensin II mouse model is particularly popular in so-called
treatment studies, in which the effects of pharmaceutical or genetic in-
terventions on aneurysm incidence, aneurysm severity, and aneurysm-
related mortality are assessed. Since 2001, 143 manuscripts have
studied the effect of some kinds of treatment in angiotensin II-infused
mice, often quantifying aneurysm presence in terms of the luminal or
external diameter change. But despite its ubiquitous use, some import-
ant differences with human AAAs exist: the latter are located on the
infrarenal rather than the suprarenal aspect of the abdominal aorta
and are characterized by a progressive evolution rather than repeated
interparietal ruptures.5,35 To avoid confusion, we therefore refer to the
angiotensin II-induced lesions as ‘dissecting AAAs’ rather than AAAs
throughout the current manuscript.36
Here, we present a meta-analysis of all manuscripts (up to 1 January
2015), in which mice have been infused with angiotensin II in order to
provoke dissecting AAA formation. In first instance, our goal was to de-
fine reference values for (i) the occurrence of dissecting AAA, (ii) the
occurrence of different severity levels within animals developing dis-
secting AAA (categorized from grade I to grade IV20), and (iii) the mor-
tality rate during angiotensin II infusion, related to aneurysm rupture.
We also report the influence of different confounding factors such as
sex, age, diet, genetic background, and dose of angiotensin II on inci-
dence and mortality rates. The second part of the manuscript focuses
on the statistically significant difference that was discovered in the inci-
dence and mortality rates of non-treated mice in treatment studies that
were designed to enhance dissecting AAA, on the one hand, and treat-
ment studies that were designed to reduce dissecting AAA, on the
other hand. This difference seems to imply that many of the reported
incidence and mortality rates in literature were biased by the purpose
of the study. We present a stratified analysis to investigate to what
extent this bias could be attributed to confounding environmental
factors, and to what extent it was related to the variability that exists
in the criteria used to define the presence of AAA. Based on these
findings, we propose alternative criteria to quantify dissecting the pres-
ence of AAA, rather than focusing on diameter alone. As such, this
manuscript aims to provide deeper insights into the interpretation of
angiotensin II-induced dissecting AAA in the past, and provide im-
proved guidelines for its interpretation in the future.
2. Methodology
2.1 Data collection
The meta-analysis included all publications available in Pubmed until
1 January 2015, using the search terms ‘mice’ or ‘mouse’, ‘aneurysm’ and
‘angiotensin’. Exclusion criteria were (i) the use of different mouse models
than angiotensin II infusion (e.g. elastase perfusion or genetic modification
without angiotensin II infusion), (ii) reports on locations of aneurysm for-
mation different from the abdominal aorta (e.g. intracranial or ascending
aneurysms), (iii) reports focused on human aneurysm or aneurysm-related
disorders (e.g. Marfan or Loeys-Dietz syndrome), (iv) review articles, (v)
letters to the editor, (vi) manuscripts that reused mice from a previous
manuscript (and had thus already been included in the analysis), and (vii)
manuscripts for which no access could be obtained.
From the remaining 194 manuscripts, the following data were retrieved
from the Methods and Results sections: sex (male/female), diet (normal/
high fat), genetic background (ApoE2/2/LdL2/2/C57Bl\6 wild type,
C57Bl\6 wild type with anti-TGF-b antibodies, and C57Bl\6 wild type
with co-infusion of b-apn), age (ranging from 4 to 72 weeks), angiotensin
II infusion dose (ranging from 150 to 3000 ng/min/kg), angiotensin II infusion
time (ranging from 3 to 84 days), the location where dissecting AAA
diameters were quantified (lumen diameter or external diameter), the
threshold of diameter increase used to define dissecting AAA incidence
(ranging from 110 to 200%), and the reference to which dissecting AAA dia-
meters were compared in order to define dissecting AAA (suprarenal dia-
meters in saline-infused control animals, baseline suprarenal diameters
prior to angiotensin II infusion, diameters of a non-diseased segment prox-
imal to the dissecting AAA, diameters of a non-diseased segment distal to
the dissecting AAA, or lumen diameters at locations where the dissecting
AAA was quantified at the external diameter). Each study was classified into
one of three categories, depending on whether its main goal was to de-
scribe aneurysm formation, to enhance aneurysm formation, or to reduce
aneurysm formation in angiotensin II-infused mice. In manuscripts designed
to describe murine aneurysm formation, angiotensin II-infused and
saline-infused mice were the only study groups. In manuscripts designed
to enhance or reduce dissecting AAA formation, the angiotensin II-infused
mice usually functioned as controls to a third group, in which the effect of
dissecting AAA was reduced or enhanced by pharmacological or genetic
treatment. Two studies could not be categorized into any of the three cat-
egories. For each study, the number of saline-infused, the number of angio-
tensin-infused, and the number of treated mice was retrieved, as well as the
reported incidence rate of mice that developed an dissecting AAA and mice
that died of aneurysm rupture in each category. If the incidence or rupture
rates were reported in the form of bar plots or percentages, an estimate
was made based on the available data, and if group size was reported as
a range, the mean value was used. Aneurysm mortality was defined as sud-
den death during the infusion period, since the pathological confirmation of
an internal bleeding due to aneurysm rupture nor its precise location (hae-
moabdomen vs. haemothorax) was mentioned in most manuscripts. Fol-
lowing the most common procedure in literature, incidence rates include
mortality rates. In several manuscripts, a number of different treatment
groups were reported. If any of the confounding factors was different be-
tween groups, these were treated as separate studies. If not, incidence rates
from different groups were added within the same study.
2.2 Statistics
Odds ratios were calculated for each confounding factor with respect to its
reference situation. Odds ratios for categorical variables, such as sex, diet,
and genetic background, compared dissecting AAA incidence or mortality
of mice with the less frequently occurring value of the confounding factor
with the incidence of ‘reference mice’ for that factor (i.e. female was com-
pared with male, high-fat diet with normal diet, and C57Bl\6 with
ApoE2/2). Continuous variables, such as age, angiotensin II dose, and
angiotensin II infusion time, were first categorized (young: 4–8 weeks,
old: 25–84 weeks; low dose: 125–749 ng/kg/min, high dose: 1251–
3000 ng/kg/min; low infusion time: ,7 days), and odds ratios subsequently
compared dissecting AAA incidence and mortality for these less frequent
values with their respective reference situation (adult: 9–24 weeks; normal
dose: 750–1250 ng/kg/min; normal infusion time: 7–28 days). Reference
measurements to define dissecting AAA incidence were considered to
be external diameters using a threshold of a 150% increase in comparison
with saline-infused controls. Odds ratios were considered significant (P,
0.05) if the 95% CI did not include the value of 1.
Since we observed an unexpected dependency of both dissecting AAA
incidence and mortality on the design of the study, we subsequently per-
formed a stratified analysis to find to what extent this dependency was re-
lated to the presence of confounding factors. First, a Fisher’s exact test was
performed to identify the environmental factors that were correlated with
study design on both a study level (i.e. quantifying how the number of stud-
ies associated with each study design was related to each confounding fac-
tor) and a mouse level (i.e. quantifying how the accumulated aneurysm
incidence and mortality for each study design was related to each con-
founding factor). Then, a stepwise stratified analysis was performed in
which the effect of these confounding factors on the odds ratios was inves-
tigated at an individual mouse level. For each factor, only those mice
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representing the respective reference situation were withheld (i.e. after
stratification for age only adult mice were withheld, after stratification for
genetic background only Apoe2/2 mice were withheld, etc.). If any of
the confounding factors was not reported, or if either the incidence rate
or the number of animals were missing, the animals were excluded from
the stratified analysis. First, we corrected the odds ratios for those factors
that were significantly correlated with study design on both a study and a
mouse level. Since a significant effect was still visible, stratification was sub-
sequently expanded to confounding factors that were only significantly cor-
related with study design on a mouse level. Finally, stratification also
included measurement-related factors.
3. Results
3.1 Metrics of the meta-analysis
In total, 291 papers were analysed. Forty-two manuscripts were ex-
cluded since they studied different mouse models, 21 manuscripts fo-
cused on human disease, 28 did not report original research, and 2
manuscripts re-used mice from a previous manuscript, whereas for 4
manuscripts no access could be obtained. Thirty-five manuscripts re-
ported several studies with varying incidence rates or confounding fac-
tors, each of which was considered as a separate entry for the
meta-analysis. In total, this approach led to a total number of 252 stud-
ies that were extracted from 194 manuscripts. An overview can be
found in Supplementary material online, Table S1. These manuscripts
were published in 64 different journals, with an average journal impact
factor of 5.7+ 3.7. Overall, the meta-analysis represents 1679
saline-infused, 4729 non-treated angiotensin II-infused, and 4057 trea-
ted angiotensin II-infused mice.
In total, 60% of the animals developed a dissecting AAA, whereas the
mortality during angiotensin II infusion (presumably related to trans-
mural rupture) was found to be 20% (Table 1). In 33 studies represent-
ing 429 dissecting AAAs, aneurysm shapes were categorized into four
different groups, ranging from grade I to grade IV, according to the
morphology criterion first described by Daugherty et al.20 In angioten-
sin II-infused mice that did not receive any additional treatment, we
found an overall incidence of 22% grade I aneurysms, 26% grade II
aneurysms, 29% grade III aneurysms, and 24% grade IV aneurysms.
3.2 The influence of environmental factors
on dissecting AAA incidence and mortality
As reported previously, dissecting AAA incidence was significantly low-
er for females than for males (Table 2 and Figure 1). Young mice
experienced a significantly lower incidence than adult mice, whereas
old mice showed a significantly higher incidence than adults. Significant-
ly less dissecting AAAs were observed in angiotensin II-infused wild-
type C57Bl\6 mice than in ApoE2/2 mice, and also LdL2/2 mice had
significantly lower incidence than ApoE2/2 mice. C57BL\6 mice that
were co-infused with angiotensin II and b-apn had an incidence rate
that was not different from that of angiotensin II-infused ApoE2/2
mice, whereas C57Bl\6 mice that were infused with angiotensin II
and injected with anti-TGF-b antibodies had a significantly higher inci-
dence than angiotensin II-infused ApoE2/2 mice.
Dissecting AAA incidence was significantly lower for mice receiving a
low dose of angiotensin II (,750 ng/kg/min) compared with those re-
ceiving a normal dose, but the difference in incidence for mice that were
infused with higher doses of angiotensin II (.1250 ng/kg/min) was not
statistically significant. A high-fat diet did not result in a statistically signifi-
cant difference in incidence compared with normal rodent chow.
Rupture rate followed the same trend as incidence for nearly all re-
ported confounding factors. Mortality during angiotensin II infusion
was significantly higher in male mice, anti-TGF-b-injected mice, and trea-
ted mice in studies designed to enhance dissecting AAA. Mortality during
angiotensin II infusion was significantly lower in wild-type C57Bl\6 mice,
LdL2/2 mice, mice receiving a low dose of angiotensin II, and treated
mice in a study designed to reduce dissecting AAA. No significant differ-
ence in mortality was found in mice co-treated with b-apn, in mice re-
ceiving a high dose of angiotensin II, or in mice on a high-fat diet. In fact,
the only confounding factor that had a different influence on mortality
than on aneurysm incidence was age. While dissecting AAA incidence
was significantly lower in young mice than in adult mice, no significant
difference in mortality could be detected. Similarly, no statistically signifi-
cant difference in mortality was found between old and adult mice.
3.3 The enhancement of reductions and the
reduction of enhancements: a short
description
The most surprising result from our meta-analysis lies in the strong re-
lation that was found between study design and incidence of dissecting
AAA in non-treated, angiotensin II-infused mice. In manuscripts that
were designed to describe murine aneurysm formation, the incidence
rate in angiotensin II-infused mice was 56%. However, in manuscripts
that were designed to enhance murine aneurysm formation, the inci-
dence rate in non-treated, angiotensin II-infused mice (that were
used as control animals in these studies) was only 35%. Compared
with aneurysm-describing studies, this difference is highly significant
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Table 1 Dissecting AAA incidence, severity, and mortality for all studies included in the meta-analysis
No. of studies No. of mice Total no. of mice Incid. (%), mice Incid. (%), studies Std. (%), studies
Incidence 187 1977 3320 60 59 31
Mortality 129 573 2865 20 18 19
Grade I 33 93 429 22 28 28
Grade II 33 110 429 26 26 24
Grade III 33 125 429 29 27 22
Grade IV 33 101 429 24 18 20
Incidence values were obtained both on an individual mouse level (Incid. mice), taking into account the amount of mice in each study, and on a study level (Incid. studies), averaging incidence
values of all studies, irrespective of the amount of mice in each study.
Std, standard deviation.
Dissecting AAA detection in Ang II-infused mice: a meta-analysis 161
and corresponds to an odds ratio of 0.43 (Table 2 and Figure 1). On the
other hand, in manuscripts that were designed to reduce murine aneur-
ysm formation, the incidence rate in non-treated mice (that equally
served as control animals in these studies) was as high as 73%. Com-
pared with aneurysm-describing studies, this difference was highly sig-
nificant as well and corresponded to an odds ratio of 2.12 (Table 2 and
Figure 1). When comparing studies designed to enhance dissecting AAA
directly with those designed to reduce it, the difference in dissecting
AAA incidence of non-treated mice was even more pronounced
(OR ¼ 0.20).
A similar trend could be observed in dissecting AAA mortality rates.
In manuscripts that were designed to describe murine aneurysm forma-
tion, the mortality was 19%. However, in manuscripts that were de-
signed to enhance murine aneurysm formation, the mortality rate in
non-treated mice was only 13%, whereas it was 25% in manuscripts
that were designed to reduce murine aneurysm formation. Both
odds ratios were significantly different from 1 (Table 2 and Figure 1).
3.4 Stratification for environmental factors
A Fisher’s exact test indicated that study design significantly correlated
with sex, genetic background, and angiotensin II dose (P, 0.05,
Table 3). More specifically, researchers tend to choose more often
male mice and avoid low doses of angiotensin II in studies designed
to reduce dissecting AAA (Figure 2). On the other hand, researchers
conducting studies designed to enhance dissecting AAA more often se-
lected LdL2/2 or C57Bl/6 mice and used lower doses of angiotensin II.
In first instance, we performed a stepwise stratified analysis, in which
we accounted for the effect of these confounding factors on both
incidence and mortality (Table 4 and Figure 3).
After stratification for sex, background, and dose (the environmental
factors significantly correlated with study design on both a study level
and a mouse level, see Table 3), incidence was still significantly lower for
studies designed to enhance dissecting AAA. Similarly, incidence was
still significantly higher for studies designed to reduce it. Further
stratification for infusion time, age and diet (all of which were only
significantly correlated with study design on a mouse level) did not
influence the odds ratios in either case (Figure 3, top). Interestingly,
the difference in mortality rates for studies designed to enhance
dissecting AAA disappeared after stratification for sex and background.
Similarly, the difference in mortality rates for studies designed to
reduce dissecting AAA disappeared after stratification for sex,
background, dose, infusion time, and diet (Figure 3, bottom).
3.5 The influence of measurement-related
factors on dissecting AAA incidence and
mortality
We were able to extract the used criterion for aneurysm incidence
from 115 out of 194 manuscripts. In the remaining studies, the exact
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Table 2 Odds ratios and 95% CIs for incidence rates (left) and mortality rates (right) of dissecting AAA in association with
environmental confounding factors (top) and measurement-related factors (bottom)
Incid. % Incid. NsI Mort. % Mort. NsM
OR 95% CI Ref. Factor Ref. Factor OR 95% CI Ref. Factor Ref. Factor
Environmental factors
C57Bl\6 background 0.16 0.13–0.21 66 24 137 24 0.20 0.11–0.33 22 5 90 16
AngII dose ,750 ng/kg/min 0.15 0.11–0.20 63 20 140 17 0.06 0.01–0.17 22 2 100 12
Female sex 0.24 0.17–0.33 62 29 163 15 0.33 0.19–0.54 21 8 107 15
Studies designed to enhance AAA 0.43 0.34–0.52 56 35 44 43 0.65 0.48–0.86 19 13 32 31
Studies designed to reduce AAA 2.12 1.76–2.56 56 73 44 100 1.43 1.15–1.78 19 25 32 66
Age ,9 weeks 0.65 0.53–0.79 61 50 103 27 0.94 0.71–1.23 21 20 72 17
AngII infusion time ,7 days 0.32 0.15–0.65 60 33 185 4 N/A 0–Inf 20 N/A 130 0
C57Bl\6 + anti-TGF-b injection 2.19 1.34–3.74 66 81 137 3 2.22 1.45–3.36 22 39 90 3
LdL2/2 background 0.66 0.51–0.85 66 56 137 21 0.51 0.34–0.74 22 13 90 18
Age .24 weeks 1.34 1.11–1.63 61 68 103 43 0.80 0.59–1.06 21 18 72 26
Dose AngII .1250 ng/kg/min 1.14 0.93–1.40 63 66 140 31 0.89 0.66–1.19 22 20 100 17
High-fat diet 1.11 0.91–1.34 59 62 154 35 1.07 0.84–1.34 20 21 104 26
C57Bl\6 + b-apn 0.87 0.53–1.43 66 62 137 3 1.08 0.59–1.88 22 23 90 3
Measurement factors
Diameter measured at lumen 1.82 1.46–2.28 59 72 92 20 1.16 0.88–1.51 19 21 57 14
Reference diameter baseline 1.78 1.41–2.26 59 72 66 20 1.07 0.80–1.42 20 21 44 14
Threshold .150% increase 0.40 0.26–0.59 62 39 95 10 0.73 0.46–1.11 21 16 58 9
Reference diameter proximal 0.61 0.43–0.87 59 47 66 7 0.78 0.48–1.25 20 16 44 6
Reference diameter distal 2.49 1.27–5.25 59 78 66 5 N/A 0–Inf 20 N/A 44 0
Reference diameter lumen 0.93 0.45–1.97 59 57 66 2 3.58 1.09–11.50 20 47 44 1
Threshold ,150% increase 0.99 0.81–1.21 62 62 95 27 0.72 0.52–0.98 21 16 58 12
Every factor is compared with its reference value (male sex, ApoE2/2 background, age 9–24 weeks, normal diet, dose 750–1250 ng/kg/min, infusion time .6 days, study designed to
describe dissecting AAA, diameter measured externally, and dissecting AAA defined as a diameter increase of 150%, in comparison with saline-infused reference animals). Odds ratios are
considered significant if the 95% CI does not contain the value of 1. Factors are listed in the order of increasing P-value for the odds ratio of dissecting AAA incidence.
Incid., incidence; Mort., mortality; OR, odds ratio; CI, confidence interval; ref., reference; NsI, number of studies reporting incidence; NsM, number of studies reporting mortality.
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criterion for dissecting AAA was either not mentioned, or we did not
manage to locate it within the manuscript. Of the analysed studies, only
84% quantified dissecting AAA dimensions, whereas 16% determined
incidence based on visual inspection of the tissue. Surprisingly, the dif-
ferent criteria used to define incidence criteria result in no less than 31
potential definitions for dissecting AAA incidence (visual inspection
plus any permutation of three diameter thresholds, five reference loca-
tions, and two measurement locations; see Figure 2).
Figure 4 shows the odds ratios of those measurement-related fac-
tors that deviate from the most frequently occurring ‘reference’
measurement. Incidence is shown to be significantly lower when
the threshold to define dissecting the presence of AAA is put higher
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Table 3 Results of Fisher’s exact test indicate to what extent each confounding factor is related to study design
NsR NsD NsE P-value
Fs Fm incid. Fm mort.
Environmental factors
Sex 120 61 52 2.2E2 05 8.3E2 54 7.7E2 07
Background 120 62 44 8.2E2 04 N\A 1.9E2 26
Ang II dose 126 68 55 1.7E2 03 2.0E2 72 6.5E2 23
Infusion time 127 68 55 1.2E2 01 1.7E2 06 1.0E + 00
Age 123 63 43 3.6E2 01 2.2E2 10 2.0E2 05
Diet 127 68 55 9.6E2 01 1.3E2 05 3.2E2 02
Measurement factors
Reference diameter 31 58 24 2.7E2 03 N\A 3.7E2 29
Threshold increase 78 32 37 2.4E2 02 2.7E2 36 1.2E2 35
Diameter location 65 32 29 1.3E2 01 7.3E2 22 4.2E2 14
Fisher’s exact test was computed both on a study level (Fs) and for dissecting AAA incidence and mortality on an individual mouse level (Fm). Corresponding histograms on a study level are
shown in Figure 2, and the corresponding P-values determined the order of stratification in Figures 3 and 5.
NsR, number of studies designed to reduce dissecting AAA, which report the indicated factor; NsD, number of studies designed to describe dissecting AAA, which report the indicated
factor; NsE, number of studies designed to enhance dissecting AAA, which report the indicated factor; Fs, Fisher’s exact test on a study level; Fm, Fisher’s exact test on an individual mouse
level; Incid., incidence; Mort., mortality; N\A, not available. Since these factors take five different values, three of which are very infrequent, the Fisher’s exact test could not be computed on
an individual mouse level.
Figure 1 Odds ratios and 95% CIs for environmental confounding factors. Every factor is compared with its reference value (male sex, ApoE2/2
background, age 9–24 weeks, normal diet, dose 750–1250 ng/kg/min, long infusion time, and study designed to describe dissecting AAA). Odds ratios
are considered significant if the CI does not contain the value of 1. Factors are shown in order of increasing P-value.
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than 150%, and when lesion diameters are compared with a prox-
imal segment of the same aorta, rather than saline-infused controls.
The incidence of dissecting AAA is significantly higher when the an-
eurysm diameter is measured at the luminal border (i.e. in vivo) than
when external diameters are measured. Also, a significantly higher
incidence was found when comparing the dissecting AAA segment
with baseline suprarenal diameters (prior to angiotensin II infusion),
and when comparing it with a distal segment. Mortality rates
showed to be much less dependent on the measurement-related
factors.
3.6 Stratification for
measurement-related factors
A Fisher’s exact test indicated that study design significantly correlated
with the reference to which the suprarenal diameter was compared
and also with the percentage increase in diameter that was used as a
threshold to define the presence of dissecting AAA (Table 3). More
specifically, researchers tend to use less stringent criteria for diameter
increase in studies designed to reduce dissecting AAA (Figure 2). Also,
researchers conducting treatment studies (be it to enhance or to re-
duce dissecting AAA) more often measure the outer diameter (rather
than the lumen) and compare suprarenal diameter values more often
with those of saline-infused mice than researchers in descriptive
studies. The difference is most outspoken in studies designed to reduce
dissecting AAA (Figure 2).
For studies designed to enhance dissecting AAA, additional strat-
ification for measurement-related factors removes the difference in
incidence with studies designed to describe dissecting AAA (Table 4
and Figure 5, top). This is the case when withholding only those stud-
ies in which the suprarenal diameter is compared with the diameter
of saline-infused mice, but also when withholding only studies in
which a diameter criterion of 150% was used, and when withholding
only studies in which the external diameter was measured (rather
than the luminal diameter). Conversely, for studies designed to re-
duce dissecting AAA, this stratification led to a further increase in
the odds ratio for both the saline reference and the external diam-
eter. For these studies, the difference in incidence only became
Figure 2 Histograms indicating the prevalence of each category for both environmental confounding factors (top six panels) and
measurement-related factors (bottom three panels) on a study level. Histograms are subdivided for three different study designs and normalized by
the number of studies, which can be found in Table 3.
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(borderline) insignificant when only those studies in which a diam-
eter criterion of 150% was used were selected. To account for the
low amount of mice remaining after such stringent stratification,
we subsequently visualized the effect of stratification for all values
of each measurement factor, ignoring any effect of environmental
confounding factors. For studies designed to reduce dissecting
AAA, the odds ratio only decreased for studies that compared dis-
secting AAA diameters with a baseline reference, for those using a
threshold of ,150%, or for those measuring the luminal diameter
(Figure 5, bottom).
4. Discussion
The last years a plethora of studies have used angiotensin II-infused
mice to study dissecting AAA in mice: 93 of the 194 studies
analysed in this meta-analysis were published between 2012 and
2015. In the first part of this meta-analysis, we provide the research
community with reference values concerning the incidence and
mortality rates of dissecting AAA in this mouse model, and report
to what extent these values are influenced by environmental
confounding factors such as sex, age, diet, genetic background,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 4 Stratification for environmental confounding factors and measurement-related factors
Reduce Enhance NsD NsR NsE
OR 95% CI OR 95% CI
AAA incidence
Male 1.88 1.52–2.31 0.34 0.27–0.43 32 94 35
ApoE2/2 + male 1.62 1.27–2.07 0.35 0.25–0.48 27 75 14
Normal dose + ApoE2/2 + male 2.01 1.49–2.70 0.50 0.33–0.75 20 57 9
Long infusion + normal dose + ApoE2/2 + male 1.83 1.35–2.48 0.45 0.30–0.69 17 57 9
Adult + long infusion + normal dose + ApoE2/2 + male 1.53 1.09–2.15 0.24 0.08–0.59 14 42 2
Normal diet + long infusion + normal dose + ApoE2/2 + male 1.89 1.38–2.60 0.52 0.33–0.81 14 52 8
Adult + normal diet + long infusion + normal dose + ApoE2/2 + male 1.61 1.13–2.29 0.25 0.09–0.64 11 38 2
Stratified + saline reference 4.90 2.65–9.26 1.56 0.75–3.27 6 20 3
Stratified + 150% increase 1.75 1.19–2.56 0.58 0.34–0.99 8 38 4
Stratified + saline reference + 150% increase 3.92 1.72–9.16 1.24 0.50–3.17 2 20 3
Stratified + saline reference + adult 3.94 1.99–8.00 0.00 0–Inf 5 13 0
Stratified + 150% increase + adult 1.35 0.87–2.07 0.53 0.16–1.74 6 29 1
Stratified + saline reference + 150% increase + adult 3.05 1.13–8.60 0.00 0–Inf 1 13 0
Stratified + saline reference + normal diet 4.56 2.46–8.64 1.56 0.75–3.27 6 19 3
Stratified + 150% increase + normal diet 1.72 1.16–2.55 0.59 0.35–1.02 6 36 4
Stratified + saline reference + 150% increase + normal diet 3.65 1.59–8.54 1.24 0.50–3.17 2 19 3
Stratified + saline reference + adult + normal diet 3.94 1.99–8.00 0.00 0–Inf 5 13 0
Stratified + 150% increase + adult + normal diet 1.37 0.88–2.13 0.54 0.16–1.78 4 28 1
Stratified + saline reference + 150% increase + adult + normal diet 3.05 1.13–8.60 0.00 0–Inf 1 13 0
Reference diameter saline 3.56 1.92–6.70 0.67 0.36–1.28 4 13 7
Reference diameter baseline 1.57 0.14–11.60 0.00 0–Inf 1 6 0
Reference diameter proximal 0.00 0–Inf 0.00 0–Inf 2 0 0
Reference diameter distal 3.67 0.78–17.80 0.00 0–Inf 3 2 0
Reference diameter lumen 0.00 0–Inf 0.00 0–Inf 1 0 0
Threshold ,150% increase 1.74 0.798–3.78 0.33 0.14–0.81 2 10 4
Threshold ¼ 150% increase 3.69 2.38–5.76 0.77 0.47–1.25 10 20 8
Threshold .150% increase 0.00 0–Inf 0.00 0–Inf 0 1 1
Diameter measured externally 4.11 2.61–6.52 0.86 0.53–1.39 9 19 9
Diameter measured at lumen 2.19 0.90–5.25 0.00 0–Inf 2 5 0
AAA mortality
Male 1.21 0.97–1.52 0.626 0.46–0.84 20 62 24
ApoE2/2 + male 1.33 1.04–1.71 1 0.68–1.46 18 47 8
Normal dose + ApoE2/2 + male 1.41 1.07–1.86 1.14 0.76–1.70 14 36 7
Long infusion + normal dose + ApoE2/2 + male 1.41 1.07–1.86 1.14 0.76–1.70 14 36 7
Adult + long infusion + normal dose + ApoE2/2 + male 1.37 1.00–1.89 1.78 1.10–2.87 11 27 3
Normal diet + long infusion + normal dose + ApoE2/2 + male 1.16 0.85–1.61 0.988 0.62–1.56 12 34 5
Adult + normal diet + long infusion + normal dose + ApoE2/2 + male 1.09 0.78–1.54 1.23 0.71–2.08 10 27 2
Factors were included in the decreasing order of significance of their correlation with study design, as determined from the Fisher’s exact test (Table 3). The ‘stratified’ case refers to long
infusion + normal dose + ApoE2/2 + male mice. Odds ratios are considered significant if the CI does not contain the value of 1.
NsD, number of studies designed to describe dissecting AAA; NsR, number of studies designed to reduce dissecting AAA; NsE, number of studies designed to enhance dissecting AAA.
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and angiotensin II dose. In the second part, we focus on the ap-
parent discrepancy in reported incidence rates for studies de-
signed to enhance and studies designed to reduce dissecting
AAA. We investigate possible causes for this potential bias, and
propose alternative criteria for dissecting AAA detection in future
research.
Figure 3 Stepwise stratification to investigate whether environmental confounding factors can explain the dependency of dissecting AAA incidence
and mortality on study design. Factors were included in a decreasing order of significance of their correlation with study design, as determined from
Fisher’s exact test on a study level (Table 3). Top panels show that dissecting AAA incidence remains significantly different after stratification, whereas
bottom panels show that dissecting AAA mortality becomes independent of study design after stratification.
Figure 4 Odds ratios and 95% CIs for measurement-related factors. Every factor is compared with its reference value (a 150% increase in dissecting
AAA external diameter, with a reference diameter obtained from the same suprarenal segment in saline-infused mice). Odds ratios are considered sig-
nificant if the CI does not contain the value of 1.
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4.1 Dissecting AAA incidence andmortality
and their confounding factors
Our meta-analysis is the first to come up with incidence, severity and
mortality rates that are representative for a large sample of mice. We
found an overall incidence rate of 60% and a mortality rate of 20%.
While both incidence rates and mortality rates vary significantly in be-
tween laboratories (as evidenced by the high SDs when calculating dis-
secting AAA incidence on a study level, Table 1), we think that these
numbers, along with the confounding factor-dependent incidence rates
provided in Table 2, can provide an important reference for future re-
searchers planning to use this mouse model. The incidence rates of
grade I– IV morphology should be interpreted with caution as these
categories have not been defined very strictly. When first introducing
the subdivision into grades I– IV, Daugherty et al.20 already stated to
have ‘arbitrarily defined aneurysms based largely on the visual charac-
teristics’. Especially the grade IV category is to be interpreted with cau-
tion, as some authors automatically include mice succumbing to
aneurysm rupture as grade IV, while others do not. Nevertheless, we
believe that our data are the first to gather representative statistics
on the distribution of these morphological features of murine
dissecting AAA, and can as such be important for the interpretation
of future results.
When it comes to confounding factors influencing dissecting AAA,
we found that incidence and mortality in angiotensin II-infused mice
are much higher in male than in female mice. This result confirms
earlier findings,37 and is also in correspondence with what is observed
in human aneurysms.1,38 Our analysis also confirms earlier reports
that C57Bl\6 mice have lower dissecting AAA incidence and mortality
than ApoE2/2 mice, whereas C57Bl\6 that are injected with
anti-TGF-b have a significantly higher dissecting AAA incidence and
mortality.39 The reason behind these observations is the subject of
ongoing discussion.40,41
We further demonstrate that although a lower dose reduces inci-
dence and mortality of dissecting AAAs, increasing the dose of angio-
tensin II plays a less important role in incidence than what is
commonly assumed.42 Even when the threshold was fixed at very
high levels (.2000 ng/kg/min), a high dose of angiotensin II did not
significantly increase dissecting AAA incidence nor mortality. This is
important information that may be used when planning future
experiments.
Figure 5 Stepwise stratification to investigate whether measurement-related confounding factors can explain the dependency of dissecting AAA in-
cidence and mortality on study design. (Top) The starting point is reference mice with additional stratification for factors significantly correlated with
study design (sex, background, and dose) and infusion time. The reference values of each measurement-related factor (saline reference, 150% increase,
and external measurement) were included in a decreasing order of significance of their correlation with study design, as determined from the Fisher’s
exact test on a study level (Table 3). The effect of including age and diet was investigated for each factor as well. (Bottom) The starting point is all mice,
without any prior stratification. The influence of stratification is subsequently shown for all values of each measurement method.
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Age turned out not to be related to the incidence of dissecting AAA
to the same extent as sex, background, and dose. While incidence was
significantly different for young and old mice, mortality was not. More-
over, the odds ratio for dissecting AAA incidence was less outspoken,
and the CI closer to 1, than for other confounding factors. The thresh-
olds to define young (,9 weeks) and old (.24 weeks) mice were
based on biological evidence,43 allowing for a reasonable distribution
between categories (Figure 2). However, if the age limits were put at
10 and 20 weeks, neither young nor old mice showed a significant dif-
ference in dissecting AAA incidence (or mortality). This indicates that
the dependency of dissecting AAA incidence on age is less robust than
its dependency on, for instance, sex or angiotensin II dose.
Surprisingly, only moderate and non-significant effects were noted
for mice on a high-fat diet. The reason might be that we treated high-fat
diet as a binary variable and did not include the amount of cholesterol
into the analysis. Most likely a significant difference would have been
obtained if a dose-dependent analysis (such as for age and angiotensin
II dose) had been performed. The results of the analysis regarding
high-fat diet should therefore be interpreted with caution.
4.2 The enhancement of reductions and
the reduction of enhancements: a short
analysis
The most surprising result of our analysis was the strong dependence
on study design that was found in both incidence and mortality of dis-
secting AAA in non-treated, angiotensin II-infused mice that were used
as control animals in treatment studies. In part, this can be explained by
an intentional selection bias, as researchers select animals with a low
incidence (e.g. low-dose, wild-type mice) when the aim of their study
is to enhance dissecting AAA, and focus on animals at higher risk
(e.g. male mice or high doses of angiotensin II) when the aim of the
study is to reduce dissecting AAA (Figure 2). Nevertheless, a stratified
analysis demonstrated that the design-dependency of aneurysm
incidence was independent of genetic background, sex, or dose of
angiotensin II. On the other hand, the design-dependency of mortality
was found to normalize after stratification (Figure 3). But while mortal-
ity is a binary variable that, in principle, cannot be interpreted wrongly,
dissecting AAA incidence is a measurement that is prone to
interpretation.
We therefore hypothesized that a possible explanation for the de-
pendency of dissecting AAA incidence on study design could be found
in a detection bias with respect to the definition (and the interpretation
of that definition) that was used to quantify dissecting the presence of
AAA. Indeed, a thorough analysis revealed the existence of no less than
30 possibilities to quantify the dilatation related to aneurismal widening
of the suprarenal segment of the aorta. On top of this, 16% of the stud-
ies did not quantify anything at all, as they simply defined dissecting the
presence of AAA after visual inspection of the postmortem tissues. Fig-
ure 4 confirms that, while the incidence of dissecting AAA is significant-
ly different for several measurement-related factors, mortality is not.
The additional stratification in Figure 5 suggests that the dependency
of dissecting AAA incidence on study design was to a great extent de-
termined by the measurement method that was used. These data are
further supported by the results of the Fisher’s exact test (Table 3),
which demonstrate that both the reference to which diameters are
compared and the threshold in percentage increase used to define dis-
secting AAA are significantly correlated with study design. The results
of these stratified analyses should be interpreted with caution due to
the relatively low number of animals remaining after stratification for
measurement-related factors. Nevertheless, this hypothesis is worry-
ing, as it suggests that dissecting AAA incidence may depend on the
method that was used to quantify it.
Another possible explanation for the dependency of incidence and
mortality on study design is publication bias. If the control group in
an experiment designed to reduce dissecting AAA has a high incidence
of dissecting AAA, then the treatment group is more likely to signifi-
cantly reduce that incidence. Conversely, when the control group re-
veals an average incidence, then it is more likely that the incidence in the
treatment group will not be significantly lower. Vice versa, if the control
group in an experiment designed to enhance dissecting AAA has a low
incidence, the treatment is more likely to be effective. Since negative
results are more difficult to publish, many of these studies will never
be submitted or accepted in academic journals, and will thus not be ac-
counted for in the meta-analysis. Such publication bias might be the rea-
son why the incidence and mortality rates of dissecting AAA in our
meta-analysis were significantly different for treatment and descriptive
studies. While hard to verify, this hypothesis is equally worrying as it
suggests that many of the statistically significant results in published
treatment studies were, in fact, chance findings.
A third hypothesis is that the dissecting AAA incidence and mortality
rates suffered from a systematic bias between treatment and control
groups that was related to the design of the studies, but was not in-
cluded in the stratification. As discussed in depth by Krauth et al.,44 add-
itional sources of bias in animal studies (other than the ones already
mentioned above) include attrition bias (i.e. not accounting for all ani-
mals included in the study), non-randomized treatment allocation, non-
blinded analysis, the use of animals with co-morbidity, non-compliance
with animal welfare requirements, the use of inappropriate statistical
models, an incorrect sample size calculation, or financial conflicts of
interest. We have not stratified for these potential sources of errors
as (i) unlike for selection bias, detection bias, or publication bias, there
was no clear hypothesis to link these factors to study design, and (ii)
each additional stratification step would reduce the number of remain-
ing animals, and hence further increase the size of the CIs. Neverthe-
less, it is important to take these potential sources of error into
account when planning future experiments.
4.3 Possible solutions and suggestions for
future research
When interpreting the results of preclinical studies investigating the ef-
fect of pharmacological or genetic treatment on dissecting AAA inci-
dence, one often implicitly assumes that the latter is an unequivocal,
straightforward observation that is not susceptible to interpretation.
Reality, however, is different. In a clinical setting, a luminal increase of
150% in aortic diameter is typically used as the cut-off criterion to de-
fine AAA incidence. This is an artificial limit that is based on the clinical
reality that smaller dilatations are at a lower risk of rupture and should
therefore not be treated since the surgery risk would outweigh the
rupture risk.45 Despite the fact that treatment studies in a preclinical
research setting function within an entirely different paradigm, the def-
inition of dissecting AAA has not been adjusted accordingly. Already in
2007, Jiang et al.46 argued that the ‘pseudoaneurysms’ induced by angio-
tensin II are a binary event, and that measures of the luminal or external
aortic diameter might not accurately reflect the development of mur-
ine dissecting AAA, especially when studying the effect of drugs on dis-
secting AAA incidence and severity. Here, we suggest two different
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strategies for both the quantification and interpretation of dissecting
AAA incidence in studies using the angiotensin II-infused ApoE2/2
mouse model:
(i) When analysing data, future researchers should refrain from re-
porting either external or luminal diameters as if they were a single
and non-biased expression of dissecting AAA incidence. Instead,
the effect of treatment studies should be quantified on a micro-
structural level, quantifying e.g. the elastin and collagen content,
the size of the intramural thrombus, or the number of branches
affected.
(ii) When interpreting data, future researchers should keep the possi-
bility of publication bias into account, and compare incidence and
mortality rates of the angiotensin II-infused control group with the
reference values provided in this meta-analysis.
4.4 Limitations
The data extraction for the meta-analysis has been performed by a sin-
gle operator (B.T.). We chose to maximize the number of animals by
including those manuscripts in which aneurysm incidence or mortality
rates were not mentioned in written text, but only in the form of bar
plots, or relative to the group size. Therefore, some of the values on
dissecting AAA incidence and mortality mentioned in Supplementary
material online, Table S1 may be prone to interpretation errors, where-
as others may have gone undetected while they were mentioned within
the manuscript. Given the sample size that was achieved, such errors
are expected to be randomly distributed and should not affect the con-
clusions of our work. We would like to point out that the number of
studies reporting incidence values was in general greater than those re-
porting mortality values. In order not to lose a significant amount of
data prior to stratification, the latter was performed for the largest pos-
sible groups in both cases. A more stringent interpretation, only taking
into account those studies that reported both incidence and mortality,
resulted in larger CIs, but did not change the interpretation of the re-
sults for dissecting AAA incidence. We did not report these results as
the odds ratios for mortality became more difficult to interpret, due to
the low number of studies remaining after stratification. On a similar
note, the wide CIs after stratification for the measurement methods in-
dicate that the number of mice remaining in this cohort after many sub-
sequent stratification steps was quite low (Figure 5 and Table 4). While
the exact numerical values of this part of the stratification should there-
fore be interpreted with caution, they do not alter the main conclu-
sions, which are supported by the Fisher’s exact test that was carried
out on a study level (Table 3).
5. Conclusions
We have performed a meta-analysis to provide overall as well as strati-
fied, confounding factor-dependent incidence, severity, and mortality
rates for dissecting AAA in angiotensin II-infused mice. We strongly be-
lieve that these numbers have the potential to serve as reference data
and will allow for a more accurate study design when planning experi-
ments using the angiotensin II-infused mouse model. The reported in-
cidence and mortality rates were higher for angiotensin II-infused mice
that served as control animals in studies designed to reduce dissecting
AAA, and lower for mice that served as control animals in studies de-
signed to enhance dissecting AAA. Stratification showed that this de-
pendency could be explained by an intentional selection bias of
environmental confounding factors (sex, dose, genetic background,
age, and diet) for dissecting AAA mortality, but not for dissecting
AAA incidence. We subsequently hypothesized that the dependency
of dissecting AAA incidence on study design may be related to the vari-
ability in methods used to quantify dissecting AAA, and that literature
may be distorted by a publication bias. We conclude that, before any
further treatment studies are performed, the translational aspects of
this mouse model should be further documented and the relevance
of diameter increase as a single quantification of dissecting AAA inci-
dence should be questioned.
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